Stereotaxis to initiate first-in-human trial for MAGiC catheter after CE Mark clinical data request

Stereotaxis, Inc.

Notified body requests clinical data for MAGiC catheter CE Mark under EU MDR; prior submission included preclinical data.
First-in-human trial to commence to support CE Mark; Stereotaxis expects to complete study before end of 2023.
Company reiterates expectation of double-digit revenue growth in 2023; strong cash position.
CEO states innovation strategy includes accessible robot and proprietary catheters for EP and endovascular interventions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.